NOW-HEALTH-INTERNATIONAL
7.6.2021 10:02:06 CEST | Business Wire | Press release
Now Health International Group, a leading International Private Medical Insurance (IPMI) provider, has announced a new program with Starr Insurance Companies, a leading global insurance company, to drive forward ambitious growth plans in Europe.
This mutually beneficial relationship combines Now Health International’s global presence and expertise in providing high quality international health insurance solutions and state of the art digital tools, including the recently launched Mobile Pass innovation, with Starr’s long-standing global knowledge and ability to deliver customised solutions across Europe through a specialised team of professionals dedicated to offering the best service to its customers.
Under the new agreement, as of 1st March 2021, Starr Insurance Companies will insure all new and renewing business across Europe. Now Health International will continue to administer the international health insurance plans, including claims handling and customer service support. All members will also continue to benefit from access to Now Health International’s award-winning digital tools.
Zahir Sharif, Managing Director, Now Health International said, “At Now Health International we are committed to further building our presence in Europe and have ambitions to expand into new markets across the region. Starr Insurance Companies, with over 100-years of heritage, expertise and existing presence across global markets, is a well-placed partner to help us achieve this goal.”
Now Health International will continue to offer its existing products to members across Europe under the new partnership, including its flagship, benefit-rich WorldCare product, and its more affordable SimpleCare product for those looking for essential health cover. There will be no changes to plan benefits, pricing, or the customer service experience as a result of this arrangement.
The new program replaces Now Health International’s previous relationship with AXA PPP Healthcare. To ensure a smooth transition process for existing members, a runoff period will be deployed until 31st December 2021, seamlessly transitioning members to the new arrangement with Starr Insurance Companies at their next plan renewal.
Michel Faucher, Chief Commercial Officer, Now Health International added, “We are very excited about our new relationship and the opportunities it presents for us in the long term. I also want to reassure our members and partners that there will be complete continuity under the new arrangements, with the same market-leading plans and benefits, high standards of service, and state of the art digital tools our European customer base have come to expect.”
Santiago Mora, Head of International Accident & Health for Starr, said, “We’re excited to be the insurance provider for Now Health International, one of the fastest growing providers of medical insurance solutions for global expatriates.”
-ENDS-
Notes to Editors: About Now Health International Group
The Now Health International Group consists of Now Health International and Best Doctors Insurance. Now Health International is one of the fastest growing providers of International Private Medical Insurance (IPMI) solutions for Global Expatriates, High-Net-Worth individuals and Companies. Now Health has offices in the UK, Malta, UAE, China, Hong Kong, Singapore and Indonesia. Best Doctors Insurance is a Bermuda/ Miami based major medical insurance provider with offices in the US, Canada and Ecuador and distribution throughout Central and Latin America, the Caribbean and Canada.
The combined business is a global top tier specialist IPMI provider, with complementary products, distribution and geographies. The operation spans four continents, with 11 sales &/or service offices, 125,000+ members, 370+ employees and 5,000+ distribution partners.
Notes to Editors: About Starr Insurance Companies
Starr Insurance Companies (or Starr) is a marketing name for the operating insurance and travel assistance companies and subsidiaries of Starr International Company, Inc. and for the investment business of C. V. Starr & Co., Inc. and its subsidiaries. Starr is a leading insurance and investment organization with a presence on six continents; through its operating insurance companies, Starr provides property, casualty, and accident and health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance. Starr’s insurance company subsidiaries domiciled in the U.S., Bermuda, China, Hong Kong, Singapore, U.K. and Malta each have an A.M. Best rating of “A” (Excellent). Starr’s Lloyd’s syndicate has a Standard & Poor’s rating of “A+” (Strong).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom